<--- Back to Details
First PageDocument Content
Nose / Allergology / Nasal spray / Pharmacology / Azelastine / Rhinitis / Olopatadine / Epistaxis / Nasal congestion / Medicine / Chemistry / Health
Date: 2014-08-21 13:04:53
Nose
Allergology
Nasal spray
Pharmacology
Azelastine
Rhinitis
Olopatadine
Epistaxis
Nasal congestion
Medicine
Chemistry
Health

These highlights do not include all the information needed to use PATANASE® Nasal Spray safely and effectively. See full prescribing information for PATANASE Nasal Spray. PATANASE (olopatadine hydrochloride) Nasal Spray

Add to Reading List

Source URL: ecatalog.alcon.com

Download Document from Source Website

File Size: 435,16 KB

Share Document on Facebook

Similar Documents

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PAZEO* safely and effectively. See full prescribing information for PAZEO. PAZEO (olopatadine hydrochloride ophthalm

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PAZEO* safely and effectively. See full prescribing information for PAZEO. PAZEO (olopatadine hydrochloride ophthalm

DocID: 1rcmh - View Document

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PAZEO* safely and effectively. See full prescribing information for PAZEO. PAZEO (olopatadine hydrochloride ophthalm

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PAZEO* safely and effectively. See full prescribing information for PAZEO. PAZEO (olopatadine hydrochloride ophthalm

DocID: 1qJA3 - View Document

DESCRIPTION PATANOL® (olopatadine hydrochloride ophthalmic solution) 0.1% is a sterile ophthalmic solution containing olopatadine, a relatively selective H1 -receptor antagonist and inhibitor of histamine release from t

DESCRIPTION PATANOL® (olopatadine hydrochloride ophthalmic solution) 0.1% is a sterile ophthalmic solution containing olopatadine, a relatively selective H1 -receptor antagonist and inhibitor of histamine release from t

DocID: NAo0 - View Document

Division: Pharmacy Services  Subject: Prior Authorization Criteria Original Development Date: Original Effective Date:

Division: Pharmacy Services Subject: Prior Authorization Criteria Original Development Date: Original Effective Date:

DocID: COdJ - View Document

CPDO Examination - Minicase 1 Patient findings: A 27-year-old female presents after an airbag injury to her right eye the previous day. Examination reveals a relative afferent pupillary defect and light-perception vision

CPDO Examination - Minicase 1 Patient findings: A 27-year-old female presents after an airbag injury to her right eye the previous day. Examination reveals a relative afferent pupillary defect and light-perception vision

DocID: CO0u - View Document